Telesis Bio manufactures and sells laboratory equipment, synthetic biology instruments, reagents and associated products and related services to pharmaceutical and academic laboratories. Co.'s solutions include: BioXp 3250 and BioXp 9600 systems, which are an end-to-end automated workstation that enables researchers to go from a DNA sequence to endpoint-ready DNA; BioXp DBC, which is an enzymatic DNA synthesis with design to endpoint-ready synthetic RNA; BioXp portal, which is an online portal that provides guided workflow and design tools for building new DNA sequences; and BioXp De Novo kits, contain the building blocks and reagents for synthetic biology workflow applications. We show 4 historical shares outstanding datapoints in our TBIO shares outstanding history coverage, used to compute TBIO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TBIO market cap history over the course of time is important for investors
interested in comparing TBIO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TBIO versus a peer is one thing; comparing
TBIO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TBIO can fluctuate over the course of history.
With this page we aim to empower investors researching TBIO by allowing them to research the TBIO market cap history. |
Free TBIO Email Alerts:
Video: The Importance of Market Cap
